-
公开(公告)号：US12070500B2
公开(公告)日：2024-08-27
申请号：US17362020
申请日：2021-06-29
Applicant: Vaccinex, Inc.
Inventor： Elizabeth E. Evans , Ernest S. Smith , Maurice Zauderer
IPC: A61K39/395 , A61P35/00 , A61P37/04 , A61K31/675 , A61K35/15 , A61K38/20 , A61K39/00 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12N5/0783 , G01N33/50
CPC classification number: A61K39/39558 , A61K39/3955 , A61P35/00 , A61P37/04 , A61K31/675 , A61K35/15 , A61K38/2013 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61K2039/572 , C07K14/4705 , C07K14/70596 , C07K16/18 , C07K16/2803 , C07K16/2818 , C07K16/2863 , C07K16/2896 , C07K16/30 , C07K16/32 , C07K16/40 , C07K2317/73 , C07K2317/76 , C12N5/0638 , C12N2501/2302 , C12N2501/998 , G01N33/5094
Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
-
2.发明授权公开(公告)号：US11534488B2
公开(公告)日：2022-12-27
申请号：US16433496
申请日：2019-06-06
Applicant: Vaccinex, Inc.
Inventor： Ernest S. Smith , Maurice Zauderer
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
Abstract: Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
-
公开(公告)号：US11274149B2
公开(公告)日：2022-03-15
申请号：US15581573
申请日：2017-04-28
Applicant: Vaccinex, Inc.
Inventor： Ernest S. Smith , Terrence Lee Fisher
Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
-
公开(公告)号：US11078295B2
公开(公告)日：2021-08-03
申请号：US16392451
申请日：2019-04-23
Applicant: Vaccinex, Inc.
Inventor： Elizabeth Evans , Ernest S. Smith , Maurice Zauderer
IPC: A61P35/00 , A61K39/395 , G01N33/50 , C07K16/28 , A61P37/04 , C07K16/32 , A61K31/675 , C07K16/40 , A61K35/15 , A61K38/20 , C07K16/30 , C12N5/0783 , C07K14/47 , C07K16/18 , C07K14/705 , A61K39/00
Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
-
公开(公告)号：US10829550B2
公开(公告)日：2020-11-10
申请号：US15953139
申请日：2018-04-13
Applicant: Vaccinex, Inc.
Inventor： Ekaterina Klimatcheva , Mark Paris , Ernest S. Smith
Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
-
Patent Agency Ranking
公开(公告)号：US20170306017A1
公开(公告)日：2017-10-26
申请号：US15581573
申请日：2017-04-28
Applicant: Vaccinex, Inc.
Inventor： Ernest S. Smith , Terrence Lee Fisher
IPC: C07K16/28 , A61K39/395 , C07K16/30 , A61K45/06 , A61K39/00
CPC classification number: C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
-
公开(公告)号：US09090709B2
公开(公告)日：2015-07-28
申请号：US13828506
申请日：2013-03-14
Applicant: VACCINEX, INC.
Inventor： Terrence Lee Fisher , Ernest S. Smith , Maurice Zauderer
IPC: C07K16/28 , C07K14/705
CPC classification number: C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K2317/34
Abstract: The invention relates to epitopes of SEMA4D and to binding agents, such as antibodies, that specifically bind to SEMA4D.
Abstract translation: 本发明涉及SEMA4D的表位和特异性结合SEMA4D的结合剂，如抗体。
-
公开(公告)号：US20150125467A1
公开(公告)日：2015-05-07
申请号：US14382410
申请日：2013-03-01
Applicant: Vaccinex, Inc.
Inventor： Ernest S. Smith , Maurice Zauderer
IPC: C07K16/24
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/565 , C07K2317/76
Abstract: Methods for treating diseases associated with CXCL13 expression, including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein, there is provided a method of treating, preventing, or reducing the exacerbation of a B-cell-mediated inflammatory condition in a subject, including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13, wherein said molecule prevents or inhibits CXCL13 activity.
Abstract translation: 本文提供了治疗与CXCL13表达相关疾病，包括某些自身免疫性和炎性疾病如干燥综合征的方法。 所述方法包括向有需要的受试者施用有效量的抑制CXCL13活性的药剂。 根据本文所述的本发明的方面，提供了治疗，预防或减少受试者中B细胞介导的炎性病症恶化的方法，包括向受试者施用有效量的分离的结合分子，其中 特异性结合CXCL13，其中所述分子预防或抑制CXCL13活性。
-
9.发明申请Use of Semaphorin-4D Binding Molecules for Treating Neurodegenerative Disorders 有权使用信号素4D结合分子治疗神经退行性疾病公开(公告)号：US20150110800A1
公开(公告)日：2015-04-23
申请号：US14519965
申请日：2014-10-21
Applicant: Vaccinex, Inc.
Inventor： Ernest S. Smith , Maurice Zauderer , William J. Bowers , Alan Jonason
IPC: C07K16/28
CPC classification number: C07K16/2896 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K2317/30 , C07K2317/56 , C07K2317/565 , C07K2317/76
Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
Abstract translation: 本文提供了减轻患有神经退行性疾病的受试者症状的方法，包括向受试者施用有效量的特异性结合信号素-4D（SEMA4D）或其Plexin-B1或Plexin-B2受体的分离的结合分子。
-
公开(公告)号：US12006364B2
公开(公告)日：2024-06-11
申请号：US17588427
申请日：2022-01-31
Applicant: Vaccinex, Inc.
Inventor： Ernest S. Smith , Terrence Lee Fisher
CPC classification number: C07K16/2803 , A61K38/1774 , A61K39/0001 , A61K39/3955 , A61K39/39558 , A61K39/4611 , A61K39/46433 , A61K45/06 , A61P25/00 , C07K16/18 , C07K16/2896 , C07K16/30 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
-
-
-
-
-
-
-
-
-
Search Results
54
records
(took 0.032 seconds)
